This article was originally published in The Gray Sheet
Executive SummaryFDA recalls Nebion's HLX-8 magnetic resonance device, which the company claimed can treat medical conditions such as cancer, carpel tunnel syndrome, migraines, arthritis and certain injuries, but is not FDA approved. Nebion "failed to provide FDA with any evidence to support these claims," FDA writes in an Oct. 3 Class I recall notice. On July 2, Nebion notified customers about the recall and instructed them to stop using the device and to report any adverse reactions or problems to FDA
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.